Skip to main content

Day: April 28, 2025

Exosens delivers strong revenue growth in Q1 2025 in a dynamic defense market environment; Fully on track to 2025 guidance

EXOSENS DELIVERS STRONG REVENUE GROWTH IN Q1 2025 IN A DYNAMIC DEFENSE MARKET ENVIRONMENT FULLY ON TRACK TO 2025 GUIDANCE HIGHLIGHTSSustained revenue growth of +21.1% to €104.9m in Q1 2025, reflecting strong like-for-like performance (+18.0%)Continued strong growth in Amplification revenue (+29.1% vs. Q1 2024), driven by a growing demand of image intensifier tubes for Defense night vision applications from NATO and Tier-1 allies forces Detection & Imaging revenue slightly down (-1.0% vs. Q1 2024), affected by temporary headwinds mostly related to Telops, the Group’s imaging systems business in Canada (+16% growth vs. Q1 2024 excluding Telops). Growth is expected to resume and accelerate throughout the remainder of the year supported by solid underlying end-market trendsAdjusted gross margin up +28.1% to €52.6m in Q1 2025 (margin...

Continue reading

Vallourec Awarded a Major Contract by Kuwait Oil Company

Press release VALLOUREC AWARDED A MAJOR CONTRACT BY KUWAIT OIL COMPANY Meudon (France), April 28, 2025 – Vallourec, a world leader in premium seamless tubular solutions, has secured a major contract to supply Oil Country Tubular Goods (OCTG) for the drilling operations of Kuwait Oil Company (KOC). This new contract represents over $130 million in potential revenue. This agreement includes the supply of carbon steel OCTG products with premium connections and proprietary steel grades, to be delivered in 2025 and 2026. Vallourec has been selected to supply the most technically advanced part of the tender in terms of grades and connections, including some of its high-torque flush premium connections. Vallourec has a historical presence in Kuwait and has been a reliable supplier to KOC, developing specific products for both its offshore and...

Continue reading

Publication annual report and convocation of the ordinary general meeting on May 28, 2025

Ghent, April 28, 2025 – 07.30 CET – Press release / Regulated information Following the publication of its annual figures on 27 March 2025, and to announce the Annual General Meeting of 28 May 2025, ABO-Group announces today its annual report for 2024. The annual report can be consulted on the ABO-Group’s website: https://www.abo-group.eu/en/investors/shareholder-information/shareholders-meetings/. There you will find the following documents:Convocation ordinary general meeting 2025 Information for the shareholders Procuration ordinary general meeting 2025 Statutory Annual accounts 2024 Report from the commissioner on the statutory financial accounts 2024 Report from the commissioner on the consolidated financial accounts 2024About ABO-Group Environment ABO-Group, opgericht in 1995 als adviesbureau voor bodemonderzoek, is uitgegroeid...

Continue reading

24/2025・Trifork Group: Weekly report on share buyback

Company announcement no. 24 / 2025Schindellegi, Switzerland – 28 April 2025 Trifork Group: Weekly report on share buyback On 28 February 2025, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buyback program runs from 4 March 2025 up to and including no later than 30 June 2025. The buyback program will not be active from 9 to 15 April 2025. For details, please see company announcement no. 7 of 28 February 2025. Under the share buyback program, Trifork will purchase shares for up to a total of DKK 14.92 million (approximately EUR 2 million). Prior to the launch of the share buyback, Trifork held 256,329 treasury shares, corresponding to 1.3% of the share...

Continue reading

argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

VYVGART® is first-and-only targeted IgG Fc-antibody fragment for CIDP First novel mechanism of action for CIDP treatment in more than 30 years CHMP positive opinion based on ADHERE data, the largest ever CIDP clinical trial European Commission (EC) decision on marketing authorization application (MAA) expected within approximately two monthsApril 28, 2025, 07:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) for subcutaneous (SC) injection as a monotherapy for the treatment of adult patients...

Continue reading

F.R.I.D.A.Y Planned Maintenance System Receives ClassNK Approval, Advancing Maritime Digitalization

Hybrid Cloud and On-Premise ERP Solution Enhances Compliance and Operational Efficiency for Vessel Management SINGAPORE, April 27, 2025 (GLOBE NEWSWIRE) — iOThree Limited (“iO3” or the “Company”) (NASDAQ: IOTR), a leading provider of maritime digital technologies including satellite connectivity and digitalization solutions in Singapore with a focus on facilitating the maritime industry towards digital transformation, today announced that its F.R.I.D.A.Y Planned Maintenance System (PMS) has received class approval from ClassNK, a leading classification society renowned for its stringent maritime standards. This certifies that the software has been approved in accordance with the functional requirements for PMS software in ClassNK’s “Guidance for the Survey and Construction of Steel Ships.” “F.R.I.D.A.Y PMS...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.